Wave Life Sciences Ltd. (NASDAQ: WVE) Stock Competitors & Peer Comparison

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, VRTX has a market cap of 139B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while VRTX trades at $547.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas VRTX's P/E ratio is 28.78. In terms of profitability, WVE's ROE is -0.50%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, WVE is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check VRTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, REGN has a market cap of 85.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while REGN trades at $828.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas REGN's P/E ratio is 18.16. In terms of profitability, WVE's ROE is -0.50%, compared to REGN's ROE of +0.14%. Regarding short-term risk, WVE is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check REGN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas VRNA's P/E ratio is -102.80. In terms of profitability, WVE's ROE is -0.50%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, WVE is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for WVE.Check VRNA's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ARGX has a market cap of 62.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ARGX trades at $1,011.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ARGX's P/E ratio is 91.26. In terms of profitability, WVE's ROE is -0.50%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, WVE is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ARGX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MRNA has a market cap of 55.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MRNA trades at $138.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MRNA's P/E ratio is -17.04. In terms of profitability, WVE's ROE is -0.50%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, WVE is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for WVE.Check MRNA's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RVMDW has a market cap of 47.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RVMDW trades at $12.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RVMDW's P/E ratio is -1.69. In terms of profitability, WVE's ROE is -0.50%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, WVE is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for WVE.Check RVMDW's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RVMD trades at $211.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RVMD's P/E ratio is -23.99. In terms of profitability, WVE's ROE is -0.50%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, WVE is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for WVE.Check RVMD's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas SGEN's P/E ratio is -57.19. In terms of profitability, WVE's ROE is -0.50%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, WVE is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check SGEN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ONC has a market cap of 39.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ONC trades at $371.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ONC's P/E ratio is 65.49. In terms of profitability, WVE's ROE is -0.50%, compared to ONC's ROE of +0.14%. Regarding short-term risk, WVE is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ONC's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ALNY trades at $236.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ALNY's P/E ratio is 42.52. In terms of profitability, WVE's ROE is -0.50%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, WVE is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for WVE.Check ALNY's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BNTX has a market cap of 28.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BNTX trades at $112.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BNTX's P/E ratio is -14.63. In terms of profitability, WVE's ROE is -0.50%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, WVE is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BNTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while INSM trades at $123.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas INSM's P/E ratio is -30.17. In terms of profitability, WVE's ROE is -0.50%, compared to INSM's ROE of -1.11%. Regarding short-term risk, WVE is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check INSM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ROIV trades at $36.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ROIV's P/E ratio is -34.59. In terms of profitability, WVE's ROE is -0.50%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, WVE is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ROIV's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while INCY trades at $127.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas INCY's P/E ratio is 17.20. In terms of profitability, WVE's ROE is -0.50%, compared to INCY's ROE of +0.30%. Regarding short-term risk, WVE is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for WVE.Check INCY's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while UTHR trades at $512.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas UTHR's P/E ratio is 18.36. In terms of profitability, WVE's ROE is -0.50%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, WVE is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for WVE.Check UTHR's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while GMAB trades at $33.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas GMAB's P/E ratio is 24.88. In terms of profitability, WVE's ROE is -0.50%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, WVE is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for WVE.Check GMAB's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BGNE's P/E ratio is -22.55. In terms of profitability, WVE's ROE is -0.50%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, WVE is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BGNE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, WVE's ROE is -0.50%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, WVE is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for WVE.Check DNA-WT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while JAZZ trades at $254.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas JAZZ's P/E ratio is 9.49. In terms of profitability, WVE's ROE is -0.50%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, WVE is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for WVE.Check JAZZ's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BBIO trades at $81.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BBIO's P/E ratio is -21.68. In terms of profitability, WVE's ROE is -0.50%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, WVE is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BBIO's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ASND trades at $251.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ASND's P/E ratio is -104.11. In terms of profitability, WVE's ROE is -0.50%, compared to ASND's ROE of +1.90%. Regarding short-term risk, WVE is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ASND's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while NBIX trades at $153.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas NBIX's P/E ratio is 22.12. In terms of profitability, WVE's ROE is -0.50%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, WVE is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check NBIX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while EXEL trades at $54.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas EXEL's P/E ratio is 15.59. In terms of profitability, WVE's ROE is -0.50%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, WVE is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for WVE.Check EXEL's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, HALO has a market cap of 12.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while HALO trades at $108.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas HALO's P/E ratio is 20.27. In terms of profitability, WVE's ROE is -0.50%, compared to HALO's ROE of +1.81%. Regarding short-term risk, WVE is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for WVE.Check HALO's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas KRTX's P/E ratio is -28.09. In terms of profitability, WVE's ROE is -0.50%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, WVE is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check KRTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BMRN has a market cap of 12.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BMRN trades at $65.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BMRN's P/E ratio is 31.28. In terms of profitability, WVE's ROE is -0.50%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, WVE is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BMRN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ARWR trades at $86.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ARWR's P/E ratio is -38.55. In terms of profitability, WVE's ROE is -0.50%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, WVE is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ARWR's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MDGL trades at $511.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MDGL's P/E ratio is -40.00. In terms of profitability, WVE's ROE is -0.50%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, WVE is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for WVE.Check MDGL's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TECH trades at $72.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TECH's P/E ratio is 37.31. In terms of profitability, WVE's ROE is -0.50%, compared to TECH's ROE of +0.09%. Regarding short-term risk, WVE is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for WVE.Check TECH's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RNAM's P/E ratio is -17.39. In terms of profitability, WVE's ROE is -0.50%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, WVE is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check RNAM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while AXSM trades at $205.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas AXSM's P/E ratio is -53.63. In terms of profitability, WVE's ROE is -0.50%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, WVE is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check AXSM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, IONS has a market cap of 10.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while IONS trades at $62.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas IONS's P/E ratio is -36.07. In terms of profitability, WVE's ROE is -0.50%, compared to IONS's ROE of -1.11%. Regarding short-term risk, WVE is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for WVE.Check IONS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PRAX trades at $368.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PRAX's P/E ratio is -28.46. In terms of profitability, WVE's ROE is -0.50%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, WVE is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check PRAX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while SMMT trades at $12.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas SMMT's P/E ratio is -11.37. In terms of profitability, WVE's ROE is -0.50%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, WVE is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for WVE.Check SMMT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while KRYS trades at $341.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas KRYS's P/E ratio is 42.82. In terms of profitability, WVE's ROE is -0.50%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, WVE is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for WVE.Check KRYS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while KYMR trades at $121.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas KYMR's P/E ratio is -37.83. In terms of profitability, WVE's ROE is -0.50%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, WVE is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for WVE.Check KYMR's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PTGX trades at $154.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PTGX's P/E ratio is 150.21. In terms of profitability, WVE's ROE is -0.50%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, WVE is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check PTGX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CYTK trades at $77.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CYTK's P/E ratio is -10.68. In terms of profitability, WVE's ROE is -0.50%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, WVE is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CYTK's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RXDX's P/E ratio is -56.47. In terms of profitability, WVE's ROE is -0.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, WVE is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check RXDX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while SYRE trades at $106.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas SYRE's P/E ratio is -54.69. In terms of profitability, WVE's ROE is -0.50%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, WVE is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check SYRE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas NUVL's P/E ratio is -21.79. In terms of profitability, WVE's ROE is -0.50%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, WVE is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for WVE.Check NUVL's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CRNX trades at $84.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CRNX's P/E ratio is -16.82. In terms of profitability, WVE's ROE is -0.50%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, WVE is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CRNX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, IMVT has a market cap of 8.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while IMVT trades at $43.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas IMVT's P/E ratio is -15.36. In terms of profitability, WVE's ROE is -0.50%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, WVE is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for WVE.Check IMVT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PCVX trades at $61.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PCVX's P/E ratio is -8.11. In terms of profitability, WVE's ROE is -0.50%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, WVE is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check PCVX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas IMGN's P/E ratio is -111.55. In terms of profitability, WVE's ROE is -0.50%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, WVE is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check IMGN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TGTX trades at $56.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TGTX's P/E ratio is 20.29. In terms of profitability, WVE's ROE is -0.50%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, WVE is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check TGTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ABVX trades at $116.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ABVX's P/E ratio is -60.88. In terms of profitability, WVE's ROE is -0.50%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, WVE is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ABVX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BPMC's P/E ratio is -51.58. In terms of profitability, WVE's ROE is -0.50%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, WVE is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BPMC's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while APGE trades at $134.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas APGE's P/E ratio is -31.13. In terms of profitability, WVE's ROE is -0.50%, compared to APGE's ROE of -0.30%. Regarding short-term risk, WVE is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check APGE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ALKS trades at $48.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ALKS's P/E ratio is 51.44. In terms of profitability, WVE's ROE is -0.50%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, WVE is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ALKS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CERE's P/E ratio is -16.47. In terms of profitability, WVE's ROE is -0.50%, compared to CERE's ROE of -0.72%. Regarding short-term risk, WVE is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CERE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while IBRX trades at $7.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas IBRX's P/E ratio is -7.81. In terms of profitability, WVE's ROE is -0.50%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, WVE is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check IBRX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RYTM trades at $111.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RYTM's P/E ratio is -35.83. In terms of profitability, WVE's ROE is -0.50%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, WVE is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check RYTM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MTSR's P/E ratio is -23.58. In terms of profitability, WVE's ROE is -0.50%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, WVE is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for WVE.Check MTSR's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CAI trades at $26.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CAI's P/E ratio is 73.42. In terms of profitability, WVE's ROE is -0.50%, compared to CAI's ROE of +0.19%. Regarding short-term risk, WVE is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for WVE.Check CAI's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while SRRK trades at $58.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas SRRK's P/E ratio is -16.87. In terms of profitability, WVE's ROE is -0.50%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, WVE is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for WVE.Check SRRK's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CGON trades at $78.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CGON's P/E ratio is -29.08. In terms of profitability, WVE's ROE is -0.50%, compared to CGON's ROE of -0.25%. Regarding short-term risk, WVE is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CGON's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MRUS's P/E ratio is -17.05. In terms of profitability, WVE's ROE is -0.50%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, WVE is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for WVE.Check MRUS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ACLX's P/E ratio is -28.27. In terms of profitability, WVE's ROE is -0.50%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, WVE is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ACLX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RETA's P/E ratio is -66.29. In terms of profitability, WVE's ROE is -0.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, WVE is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for WVE.Check RETA's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while BLTE trades at $158.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas BLTE's P/E ratio is -84.96. In terms of profitability, WVE's ROE is -0.50%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, WVE is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check BLTE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CNTA's P/E ratio is -22.63. In terms of profitability, WVE's ROE is -0.50%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, WVE is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CNTA's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while COGT trades at $36.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas COGT's P/E ratio is -17.17. In terms of profitability, WVE's ROE is -0.50%, compared to COGT's ROE of -0.73%. Regarding short-term risk, WVE is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for WVE.Check COGT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ORKA has a market cap of 6.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ORKA trades at $102.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ORKA's P/E ratio is -52.79. In terms of profitability, WVE's ROE is -0.50%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, WVE is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for WVE.Check ORKA's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while DNTH trades at $110.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas DNTH's P/E ratio is -26.52. In terms of profitability, WVE's ROE is -0.50%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, WVE is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for WVE.Check DNTH's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ERAS trades at $17.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ERAS's P/E ratio is -18.92. In terms of profitability, WVE's ROE is -0.50%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, WVE is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for WVE.Check ERAS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TVTX trades at $65.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TVTX's P/E ratio is -144.93. In terms of profitability, WVE's ROE is -0.50%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, WVE is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check TVTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PTCT trades at $71.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PTCT's P/E ratio is -30.50. In terms of profitability, WVE's ROE is -0.50%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, WVE is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for WVE.Check PTCT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MIRM trades at $96.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MIRM's P/E ratio is -6.65. In terms of profitability, WVE's ROE is -0.50%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, WVE is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check MIRM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while XENE trades at $60.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas XENE's P/E ratio is -12.89. In terms of profitability, WVE's ROE is -0.50%, compared to XENE's ROE of -0.44%. Regarding short-term risk, WVE is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check XENE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, DFTX has a market cap of 5.7B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while DFTX trades at $43.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas DFTX's P/E ratio is N/A. In terms of profitability, WVE's ROE is -0.50%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, WVE is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check DFTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while LGND trades at $280.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas LGND's P/E ratio is 30.76. In terms of profitability, WVE's ROE is -0.50%, compared to LGND's ROE of +0.20%. Regarding short-term risk, WVE is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for WVE.Check LGND's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CDTX's P/E ratio is -19.77. In terms of profitability, WVE's ROE is -0.50%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, WVE is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CDTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, WVE's ROE is -0.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, WVE is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ABCM's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ISEE's P/E ratio is -22.44. In terms of profitability, WVE's ROE is -0.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, WVE is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ISEE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CRSP trades at $57.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CRSP's P/E ratio is -11.99. In terms of profitability, WVE's ROE is -0.50%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, WVE is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for WVE.Check CRSP's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas APLS's P/E ratio is 38.35. In terms of profitability, WVE's ROE is -0.50%, compared to APLS's ROE of +0.40%. Regarding short-term risk, WVE is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for WVE.Check APLS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ACAD trades at $29.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ACAD's P/E ratio is 13.36. In terms of profitability, WVE's ROE is -0.50%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, WVE is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ACAD's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while DYN trades at $25.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas DYN's P/E ratio is -8.07. In terms of profitability, WVE's ROE is -0.50%, compared to DYN's ROE of -0.64%. Regarding short-term risk, WVE is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check DYN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while EWTX trades at $44.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas EWTX's P/E ratio is -24.17. In terms of profitability, WVE's ROE is -0.50%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, WVE is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check EWTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TERN's P/E ratio is -51.41. In terms of profitability, WVE's ROE is -0.50%, compared to TERN's ROE of -0.20%. Regarding short-term risk, WVE is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check TERN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas FOLD's P/E ratio is -161.00. In terms of profitability, WVE's ROE is -0.50%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, WVE is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for WVE.Check FOLD's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas AKRO's P/E ratio is -14.57. In terms of profitability, WVE's ROE is -0.50%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, WVE is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for WVE.Check AKRO's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PBLS trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PBLS's P/E ratio is -43.67. In terms of profitability, WVE's ROE is -0.50%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, WVE is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for WVE.Check PBLS's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ALPN's P/E ratio is -101.52. In terms of profitability, WVE's ROE is -0.50%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, WVE is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ALPN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CELC trades at $90.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CELC's P/E ratio is -21.11. In terms of profitability, WVE's ROE is -0.50%, compared to CELC's ROE of -3.51%. Regarding short-term risk, WVE is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CELC's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ELVN trades at $61.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ELVN's P/E ratio is -36.62. In terms of profitability, WVE's ROE is -0.50%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, WVE is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for WVE.Check ELVN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while RLAY trades at $19.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas RLAY's P/E ratio is -12.59. In terms of profitability, WVE's ROE is -0.50%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, WVE is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for WVE.Check RLAY's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while AMLX trades at $38.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas AMLX's P/E ratio is -25.43. In terms of profitability, WVE's ROE is -0.50%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, WVE is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check AMLX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas OPT's P/E ratio is -1.52. In terms of profitability, WVE's ROE is -0.50%, compared to OPT's ROE of +1.18%. Regarding short-term risk, WVE is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for WVE.Check OPT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas PRTC's P/E ratio is -3.78. In terms of profitability, WVE's ROE is -0.50%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, WVE is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for WVE.Check PRTC's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MRTX's P/E ratio is -4.82. In terms of profitability, WVE's ROE is -0.50%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, WVE is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check MRTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while MANE trades at $98.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas MANE's P/E ratio is -31.31. In terms of profitability, WVE's ROE is -0.50%, compared to MANE's ROE of -0.29%. Regarding short-term risk, WVE is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for WVE.Check MANE's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while ADPT trades at $25.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas ADPT's P/E ratio is -62.32. In terms of profitability, WVE's ROE is -0.50%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, WVE is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for WVE.Check ADPT's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TNGX trades at $24.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TNGX's P/E ratio is -29.53. In terms of profitability, WVE's ROE is -0.50%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, WVE is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for WVE.Check TNGX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while TLX trades at $11.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas TLX's P/E ratio is 121.92. In terms of profitability, WVE's ROE is -0.50%, compared to TLX's ROE of -0.02%. Regarding short-term risk, WVE is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check TLX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while VKTX trades at $33.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas VKTX's P/E ratio is -7.13. In terms of profitability, WVE's ROE is -0.50%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, WVE is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check VKTX's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while LEGN trades at $20.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas LEGN's P/E ratio is -30.79. In terms of profitability, WVE's ROE is -0.50%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, WVE is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for WVE.Check LEGN's competition here

Wave Life Sciences Ltd. (NASDAQ: WVE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WVE stands at 1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, WVE is priced at $5.12 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WVE currently has a P/E ratio of -4.83, whereas CPRX's P/E ratio is 12.30. In terms of profitability, WVE's ROE is -0.50%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, WVE is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for WVE.Check CPRX's competition here